Media coverage about Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zealand Pharma A/S – American Depositary Shares earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.7016069520737 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ ZEAL) traded up $0.52 during trading hours on Friday, hitting $14.87. 5,142 shares of the stock were exchanged, compared to its average volume of 13,128. Zealand Pharma A/S – American Depositary Shares has a 12 month low of $12.45 and a 12 month high of $20.37.
Several research analysts have commented on ZEAL shares. Needham & Company LLC restated a “buy” rating and issued a $26.00 target price on shares of Zealand Pharma A/S – American Depositary Shares in a research report on Monday, October 16th. Zacks Investment Research raised shares of Zealand Pharma A/S – American Depositary Shares from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Wednesday, November 15th. Finally, Goldman Sachs Group assumed coverage on shares of Zealand Pharma A/S – American Depositary Shares in a research note on Wednesday, September 27th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Zealand Pharma A/S – American Depositary Shares has an average rating of “Buy” and a consensus price target of $24.75.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-zealand-pharma-as-american-depositary-shares-zeal-share-price.html.
Zealand Pharma A/S – American Depositary Shares Company Profile
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.
Receive News & Ratings for Zealand Pharma A/S - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.